Helmholtz International Fellow Award for Professor Yehudit Bergman from Israel

June 18, 2015

The Israeli immunologist and cancer researcher Professor Yehudit Bergman of the Hebrew University of Jerusalem (HUJI), Israel, has been honored with the Helmholtz International Fellow Award for her excellent research. In a prize ceremony at the MDC Max Delbrück Center for Molecular Medicine in the Helmholtz Association in Berlin, Germany, MDC's interim director Professor Thomas Sommer presented the certificate to her on Thursday, June 18th, 2015. The prize had already been awarded to her in 2013, but Professor Bergman was not able to accept it personally until now.

The award allows Professor Bergman to strengthen her already existing cooperation with the MDC. She is one of several outstanding researchers from abroad who received the award, each of which is endowed with 20,000 euros. Professor Thomas Sommer lauded Professor Bergmann's achievements as an internationally recognized expert in epigenetics. Epigenetics describes mechanisms which do not alter the DNA sequence, but regulate when and which genes are transcribed and turned on.

In her research, Professor Bergman focuses on two key topics: the role of epigenetics in the development of the immune system and the involvement of epigenetic mechanisms in stem cells and cancer. For years she has worked closely with the cancer researcher and immunologist Professor Klaus Rajewsky of the MDC. She also cooperates with the epigeneticist Professor Frank Lyko of the German Cancer Research Center (DKFZ) in Heidelberg, which like the MDC is a member of the Helmholtz Association. This joint Helmholtz-Israel project focuses on inflammatory bowel disease.

In addition, Professor Bergman has played a significant role in establishing the German-Israeli Helmholtz Research School "Frontiers in Cell Signaling and Gene Regulation" (SignGene), which the MDC, the Hebrew University and the Technion - Israel Institute of Technology in Haifa founded in January 2013. Other partners are the Humboldt-Universität zu Berlin (HU) and the Charité - Universitätsmedizin Berlin. The international research school for young scientists is to run until 2019. It marks a high point of many years of close scientific relations between the MDC and its partners in Israel.

Yehudit Bergman was born in Tel Aviv, Israel. She completed her PhD studies in immunology at the Weizmann Institute of Science in Rehovot, Israel, in 1980. She then trained in the USA as a postdoc, first in immunology at Stanford University in California, and then in molecular biology at the Massachusetts Institute of Technology (MIT) in Cambridge. Yehudit Bergman is a full professor at the Hebrew University Medical School in Jerusalem, where she holds the Dr. Emanuel Rubin Chair in Medical Science. She is an elected representative of the Medical School to the Hebrew University Senate. In 2004 she was elected a member of the European Molecular Biology Organization (EMBO) in Heidelberg.
-end-
Contact:
Barbara Bachtler
Press Department
Max Delbrück Center for Molecular Medicine in the Helmholtz Association
Robert-Rössle-Straße 10
13125 Berlin
Germany
Phone: +49 (0) 30 94 06 - 38 96
Fax: +49 (0) 30 94 06 - 38 33
e-mail: presse@mdc-berlin.de
http://www.mdc-berlin.de/en

Max Delbrück Center for Molecular Medicine in the Helmholtz Association

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.